Interplay between hypercholesterolaemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice

Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

(2018) Paul M Ridker et al.   LANCET

PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia

(2017) Sophie J. Bernelot Moens et al.   EUROPEAN HEART JOURNAL

Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

(2017) Paul M Ridker et al.   LANCET

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

(2017) Robert P Giugliano et al.   LANCET

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

(2017) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: a meta-analysis of 16 randomized controlled treatment arms

(2016) Amirhossein Sahebkar et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

(2016) Alberico L. Catapano et al.   EUROPEAN HEART JOURNAL

Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions

(2016) Michael G. Silverman et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis

(2016) Steven E. Nissen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Differential Expression of PCSK9 Modulates Infection, Inflammation, and Coagulation in a Murine Model of Sepsis

(2016) Dhruva J. Dwivedi et al.   SHOCK

Sirolimus Therapy Is Associated with Elevation in Circulating PCSK9 Levels in Cardiac Transplant Patients

(2016) Vinaya Simha et al.   Journal of Cardiovascular Translational Research

2016 European Guidelines on cardiovascular disease prevention in clinical practice

(2016) et al.   European Journal of Preventive Cardiology

Lipopolysaccharide Is Cleared from the Circulation by Hepatocytes via the Low Density Lipoprotein Receptor

(2016) Elena Topchiy et al.   PLoS One

Novel methodologies for biomarker discovery in atherosclerosis

(2015) Imo E. Hoefer et al.   EUROPEAN HEART JOURNAL

Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

(2015) Erik S. Stroes et al.   EUROPEAN HEART JOURNAL

Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line

(2015) Massimiliano Ruscica et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Local effects of human PCSK9 on the atherosclerotic lesion

(2015) Ilaria Giunzioni et al.   JOURNAL OF PATHOLOGY

Anti-inflammatory therapies for atherosclerosis

(2015) Magnus Bäck et al.   Nature Reviews Cardiology

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

(2015) Jennifer G. Robinson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every Two Weeks Dosing from Phase 2 Trials)

(2014) Daniel Gaudet et al.   AMERICAN JOURNAL OF CARDIOLOGY

Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease

(2014) Sha Li et al.   ATHEROSCLEROSIS

The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study

(2014) A. C. Morton et al.   EUROPEAN HEART JOURNAL

Biomechanical factors in atherosclerosis: mechanisms and clinical implications

(2014) Brenda R. Kwak et al.   EUROPEAN HEART JOURNAL

Thrombosis formation on atherosclerotic lesions and plaque rupture

(2014) L. Badimon et al.   JOURNAL OF INTERNAL MEDICINE

Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin

(2014) Susan Kühnast et al.   JOURNAL OF LIPID RESEARCH

Pro-Inflammatory Interleukin-1 Genotypes Potentiate the Risk of Coronary Artery Disease and Cardiovascular Events Mediated by Oxidized Phospholipids and Lipoprotein(a)

(2014) Sotirios Tsimikas et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Anti-Inflammatory Activity of Ezetimibe by Regulating NF-κB/MAPK Pathway in THP-1 Macrophages

(2014) Li Qin et al.   PHARMACOLOGY

The Effects of the Mediterranean Diet on Biomarkers of Vascular Wall Inflammation and Plaque Vulnerability in Subjects with High Risk for Cardiovascular Disease. A Randomized Trial

(2014) Rosa Casas et al.   PLoS One

PCSK9 is a critical regulator of the innate immune response and septic shock outcome

(2014) K. R. Walley et al.   Science Translational Medicine

Rationale and design of the Cardiovascular Inflammation Reduction Trial: A test of the inflammatory hypothesis of atherothrombosis

(2013) Brendan M. Everett et al.   AMERICAN HEART JOURNAL

The Effect of Fenofibrate on Lymphocyte Release of Proinflammatory Cytokines and Systemic Inflammation in Simvastatin-Treated Patients with Atherosclerosis and Early Glucose Metabolism Disturbances

(2013) Robert Krysiak et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Depletion of FOXP3+ regulatory T cells promotes hypercholesterolemia and atherosclerosis

(2013) Roland Klingenberg et al.   JOURNAL OF CLINICAL INVESTIGATION

Toll-like receptors in atherosclerosis: a ‘Pandora's box’ of advances and controversies

(2013) Jennifer E. Cole et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Inflammation in Atherosclerosis

(2012) Peter Libby   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Interleukin-18: a potent pro-inflammatory cytokine in atherosclerosis: EXPERT'S PERSPECTIVE

(2012) L. Badimon   CARDIOVASCULAR RESEARCH

Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease

(2012) Erik Ingelsson et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Interleukin-1 in the pathogenesis and treatment of inflammatory diseases

(2011) C. A. Dinarello   BLOOD

Macrophages in the Pathogenesis of Atherosclerosis

(2011) Kathryn J. Moore et al.   CELL

Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib

(2011) M. Back et al.   EUROPEAN HEART JOURNAL

Atherosclerosis: current pathogenesis and therapeutic options

(2011) Christian Weber et al.   NATURE MEDICINE

Cardiovascular Risk with Non-Steroidal Anti-Inflammatory Drugs: Systematic Review of Population-Based Controlled Observational Studies

(2011) Patricia McGettigan et al.   PLOS MEDICINE

Effect of Ezetimibe on Hepatic Fat, Inflammatory Markers, and Apolipoprotein B-100 Kinetics in Insulin-Resistant Obese Subjects on a Weight Loss Diet

(2010) D. C. Chan et al.   DIABETES CARE

NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals

(2010) Peter Duewell et al.   NATURE

Systematic review and meta-analysis: Anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis

(2010) Cheryl Barnabe et al.   ARTHRITIS CARE & RESEARCH

Toll-Like Receptor-2 Mediates Inflammation and Matrix Degradation in Human Atherosclerosis

(2009) Claudia Monaco et al.   CIRCULATION

Changes in C-reactive protein from low-fat diet and/or physical activity in men and women with and without metabolic syndrome

(2009) Sarah M. Camhi et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Effect of Intensive Atorvastatin Therapy on Prostaglandin E2 Levels and Metalloproteinase-9 Activity in the Plasma of Patients With Non-ST-Elevation Acute Coronary Syndrome††Conflicts of interest: Drs. Egido and Tuñón have participated on advisory boards and have been invited speakers for Pfizer.

(2008) Almudena Gómez-Hernández et al.   AMERICAN JOURNAL OF CARDIOLOGY

Inflammation stimulates the expression of PCSK9

(2008) Kenneth R. Feingold et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS